These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 2582017)

  • 41. Efficacy of intravenous disopyramide in acute cardiac arrhythmias.
    De Backer M; Stoupel E; Kahn RJ
    Eur J Clin Pharmacol; 1981 Jan; 19(1):11-8. PubMed ID: 6161824
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man.
    Barbey JT; Thompson KA; Echt DS; Woosley RL; Roden DM
    Circulation; 1988 Feb; 77(2):380-91. PubMed ID: 3123092
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Electrophysiologic and electrocardiographic effects, efficacy and safety of encainide in malignant ventricular arrhythmias associated with coronary artery disease.
    Weintraub AR; Manolis AS; Estes NA
    Am J Cardiol; 1990 Oct; 66(12):947-53. PubMed ID: 2121017
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prophylaxis against ventricular arrhythmias in suspected acute myocardial infarction: a comparison of tocainide and disopyramide.
    Allen-Narker RA; Roberts CJ; Marshall AJ; Jordan SC; Barritt DW; Goodfellow RM
    Br J Clin Pharmacol; 1984 Nov; 18(5):725-32. PubMed ID: 6439233
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of disopyramide and mexiletine for better tolerance and additive effects for treatment of ventricular arrhythmias.
    Kim SG; Mercando AD; Tam S; Fisher JD
    J Am Coll Cardiol; 1989 Mar; 13(3):659-64. PubMed ID: 2918173
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Comparison of the efficacy of moricizine and disopyramide in the treatment of ventricular extrasystoles].
    Fauchier JP; Babuty D; Rouesnel P; Cosnay P; Estepo J
    Arch Mal Coeur Vaiss; 1991 Apr; 84(4):553-60. PubMed ID: 1712193
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
    Akhtar M; Breithardt G; Camm AJ; Coumel P; Janse MJ; Lazzara R; Myerburg RJ; Schwartz PJ; Waldo AL; Wellens HJ
    Circulation; 1990 Mar; 81(3):1123-7. PubMed ID: 1689621
    [No Abstract]   [Full Text] [Related]  

  • 48. Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia.
    Mason JW; Peters FA
    Circulation; 1981 Mar; 63(3):670-5. PubMed ID: 6780234
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Encainide. A review of its pharmacological properties and therapeutic efficacy.
    Brogden RN; Todd PA
    Drugs; 1987 Nov; 34(5):519-38. PubMed ID: 3121275
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia.
    Kuck KH; Kunze KP; Schlüter M; Duckeck W
    Am J Cardiol; 1988 Dec; 62(19):37L-44L. PubMed ID: 3144166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized, double-blind, parallel group comparison of disopyramide phosphate and quinidine in patients with cardiac arrhythmias.
    Arif M; Laidlaw JC; Oshrain C; Willis PW; Nissen CH; McDermott DJ; Smith WS; Karim A; Wilson RR
    Angiology; 1983 Jun; 34(6):393-400. PubMed ID: 6408949
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New drugs for treatment of ventricular arrhythmias.
    Heger JJ; Prystowsky EN; Zipes DP
    Heart Lung; 1981; 10(3):475-83. PubMed ID: 6785255
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.
    Carey EL; Duff HJ; Roden DM; Primm RK; Wilkinson GR; Wang T; Oates JA; Woosley RL
    J Clin Invest; 1984 Feb; 73(2):539-47. PubMed ID: 6421879
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
    Roden DM; Lee JT; Woosley RL; Echt DS
    Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the effects of placebo and encainide on programmed electrical stimulation and ventricular arrhythmia frequency.
    Duff HJ; Roden DM; Dawson AK; Oates JA; Smith RF; Woosley RL
    Am J Cardiol; 1982 Aug; 50(2):305-12. PubMed ID: 6808820
    [No Abstract]   [Full Text] [Related]  

  • 56. Flecainide and encainide.
    Furlanello F; Vergara G; Bettini R; Mosna G; Gramegna L; Disertori M
    Eur Heart J; 1987 Mar; 8 Suppl A():33-40. PubMed ID: 3107989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recruitment and baseline description of patients in the Cardiac Arrhythmia Pilot Study. The Cardiac Arrhythmia Pilot Study (CAPS) investigators.
    Am J Cardiol; 1988 Apr; 61(10):704-13. PubMed ID: 2451414
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cibenzoline for treatment of ventricular arrhythmias: a double-blind placebo-controlled study.
    Kostis JB; Krieger S; Moreyra A; Cosgrove N
    J Am Coll Cardiol; 1984 Aug; 4(2):372-7. PubMed ID: 6376595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relation of baseline characteristics to suppression of ventricular arrhythmias during placebo and active antiarrhythmic therapy in patients after myocardial infarction.
    Anderson JL; Hallstrom AP; Griffith LS; Ledingham RB; Reiffel JA; Yusuf S; Barker AH; Fowles RE; Young JB
    Circulation; 1989 Mar; 79(3):610-9. PubMed ID: 2465099
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Suppression of incessant supraventricular tachycardia by intravenous and oral encainide.
    Brugada P; Abdollah H; Wellens HJ
    J Am Coll Cardiol; 1984 Dec; 4(6):1255-60. PubMed ID: 6438205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.